These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 24106994

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia.
    Silva DG, Belini Junior E, Torres Lde S, Ricci Júnior O, Lobo Cde C, Bonini-Domingos CR, de Almeida EA.
    Blood Cells Mol Dis; 2011 Jun 15; 47(1):23-8. PubMed ID: 21489839
    [Abstract] [Full Text] [Related]

  • 5. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P, Barretto de Mello A, Figueiredo MS.
    Am J Hematol; 2005 Mar 15; 78(3):243-4. PubMed ID: 15726590
    [Abstract] [Full Text] [Related]

  • 6. DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype.
    da Silva Rocha LB, Dias Elias DB, Barbosa MC, Bandeira IC, Gonçalves RP.
    Mutat Res; 2012 Dec 12; 749(1-2):48-52. PubMed ID: 22918118
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Influence of βS allele in the lipid peroxidation and antioxidant capacity parameters.
    Shimauti EL, Belini Junior E, Baracioli LM, Souza EM, Granzotto D, Almeida EA, Silva DG, Ricci Junior O, Bonini-Domingos CR.
    Int J Lab Hematol; 2014 Apr 12; 36(2):205-12. PubMed ID: 24118969
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov 12; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 13. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Nov 12; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 14. Effect of N(Epsilon)-(carboxymethyl)lysine on Laboratory Parameters and Its Association with β S Haplotype in Children with Sickle Cell Anemia.
    Ndidi US, Adanho CSA, Santiago RP, Yahouédéhou SCMA, Santana SS, Mafili VV, Pitanga TN, Fonseca CA, Ferreira JRD, Adorno EV, Lyra IM, Adekile AD, Barbosa CG, Goncalves MS.
    Dis Markers; 2019 Nov 12; 2019():1580485. PubMed ID: 31636731
    [Abstract] [Full Text] [Related]

  • 15. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
    el-Hazmi MA, al-Momen A, Warsy AS, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F.
    Acta Haematol; 1995 Nov 12; 93(2-4):57-61. PubMed ID: 7543719
    [Abstract] [Full Text] [Related]

  • 16. Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters.
    Yahouédéhou SCMA, Carvalho MOS, Oliveira RM, Santiago RP, da Guarda CC, Carvalho SP, Ferreira JRD, Aleluia MM, Adorno EV, Gonçalves MS.
    Dis Markers; 2018 Nov 12; 2018():6105691. PubMed ID: 29619129
    [Abstract] [Full Text] [Related]

  • 17. Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
    Saleh AW, Velvis HJ, Gu LH, Hillen HF, Huisman TH.
    Acta Haematol; 1997 Nov 12; 98(3):125-9. PubMed ID: 9352741
    [Abstract] [Full Text] [Related]

  • 18. Influence of βS-Globin Haplotypes and Hydroxyurea on Arginase I Levels in Sickle Cell Disease.
    Moreira JA, Machado RP, Laurentino MR, Lemes RP, Barbosa MC, Santos TE, Bandeira IC, Martins AM.
    Dis Markers; 2016 Nov 12; 2016():9172726. PubMed ID: 27274608
    [Abstract] [Full Text] [Related]

  • 19. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
    Al-Nood HA, Al-Khawlani MM, Al-Akwa A.
    Hemoglobin; 2011 Nov 12; 35(1):13-21. PubMed ID: 21250877
    [Abstract] [Full Text] [Related]

  • 20. Atypical beta(s) haplotypes are generated by diverse genetic mechanisms.
    Zago MA, Silva WA, Dalle B, Gualandro S, Hutz MH, Lapoumeroulie C, Tavella MH, Araujo AG, Krieger JE, Elion J, Krishnamoorthy R.
    Am J Hematol; 2000 Feb 12; 63(2):79-84. PubMed ID: 10629573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.